Crucell (CRXLY) Stock Price, News & Analysis

Company Overview

Crucell NV is a Netherlands-based biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. The Company's product candidates include flu-mAb, an antibody product effective against a range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination, all produced on its PER.C6 human cell-line technology. It focuses on the paediatric, travel and endemic, and respiratory fields. Its core product portfolio includes Quinvaxem, a liquid pentavalent vaccine against five important childhood diseases; Hepavax-Gene, a hepatitis B vaccine; Epaxal, an aluminum-free hepatitis A vaccine; Vivotif and Dukoral, oral vaccines against typhoid and cholera; and Inflexal V, a virosomal adjuvanted vaccine against influenza. It has offices in the Netherlands, China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the United Kingdom, the United States and Vietnam.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRXLY Stock Analysis - Frequently Asked Questions

How do I buy shares of Crucell?

Shares of CRXLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CRXLY
• Previous Symbol: NASDAQ:CRXL
• CIK: N/A
• Web: N/A
• Phone: +31-71-5199100
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A